Tech Company Financing Transactions
Nura Bio Funding Round
The Column Group, Euclidean Capital and Samsara BioCapital participated in a $68 million funding round for Nura Bio. The round was announced on 9/17/2024.
Transaction Overview
Company Name
Announced On
9/17/2024
Transaction Type
Venture Equity
Amount
$68,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The new capital is enough to get Nura Bio's lead program to the end of the proof-of-biology clinical trial.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
171 Oyster Point Blvd 401
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Nura Bio was conceived in 2018 by The Column Group and its scientific founders to revolutionize the treatment of neurological diseases with novel, life-changing neuroprotective medicines. By transforming recent scientific breakthroughs in axonal degeneration and neuroimmune regulation into neuroprotective medicines, we aim to offer renewed hope for those affected by serious neurological diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shilpa Sambashivan
VP - Bus. Development
David Lau
Browse more venture capital transactions:
Prev: 9/17/2024: Cybord venture capital transaction
Next: 9/17/2024: Martian venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record tech company VC transactions. VC transactions on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs